1. Introduction {#sec1-ijms-16-20560}
===============

Articular cartilage is an avascular tissue whose functional properties of mechanical support and joint lubrication are dependent on the functional integrity of its extracellular matrix (ECM). Cartilage ECM is rich in fibrillar collagens, especially type II, large aggregating proteoglycans and smaller hydrophilic macromolecules that confer lubricative and swelling properties to the tissue \[[@B1-ijms-16-20560]\]. Under normal physiological conditions chondrocytes maintain a delicate equilibrium between the synthesis and degradation of the ECM components, thus regulating the structural and functional integrity of cartilage \[[@B2-ijms-16-20560]\]. Cartilage is an avascular tissue with limited regenerative ability. Furthermore, in degenerative joint diseases there is evidence of cell death in chondrocytes, with consequent repercussions on tissue maintenance and functionality. Apoptotic cell death has been detected in osteoarthritic (OA) cartilage; this was associated with matrix degradation and calcification, which suggests a role for cell death/survival in OA pathogenesis. In contrast to necrotic cell death, apoptosis is programmed, orderly and does not induce inflammation. Apoptosis requires energy and is generally important for tissue homeostasis during the life course of an individual \[[@B3-ijms-16-20560]\]. Apoptosis represents a form of programmed cell death in which a pre-determined sequence of events leads to the elimination of old, unnecessary and unhealthy cells, without releasing harmful substances into the surrounding area \[[@B4-ijms-16-20560]\]. Cells that are undergoing apoptosis exhibit a characteristic pattern of morphologic changes, including cell shrinkage, condensation, fragmentation of the nucleus and bubbling of the plasma membrane, known as "blebbing", chromatin condensation and nucleosomal fragmentation \[[@B5-ijms-16-20560]\]. The crucial function of apoptotic mechanisms in cartilage degeneration and the involvement of apoptosis in various conditions associated with OA have been thoroughly explored \[[@B6-ijms-16-20560],[@B7-ijms-16-20560],[@B8-ijms-16-20560],[@B9-ijms-16-20560]\].

2. Methods {#sec2-ijms-16-20560}
==========

In this review, we analysed published articles from the most recent literature, providing a balanced and comprehensive overview of the most important discoveries in relation to pathogenesis and possible biomarkers and target molecules for the treatment of OA. Subsequently the selected articles were divided in "Osteoarthritis", "Chondrocytes apoptosis in Osteoarthritis", "Biomarkers of chondrocyte degeneration" and "Autophagy", to structure the review and render it more understandable for interested researchers by providing a detailed and schematic overview of the most relevant studies that have been done in this field. The literature search and the manuscript writing were done between December 2014 and August 2015. The databases used were PubMed, Scopus, Web of Science and Google Scholar using appropriate keywords (chondrocyte death, apoptosis, osteoarthritis, autophagy, biomarkers). Out of approximately 220 papers (original articles, systematic and meta-analysis reviews), 81 were chosen and considered appropriate for this focused review. Other papers, related to the chosen keywords, were discarded, as they were considered to be outside the scope of the research. The time period chosen for the literature search was from 1998 until 2015. The bibliographic research has been divided into four different steps and has followed an inductive reasoning. In the first step, the research was focused on papers regarding "osteoarthritis"; in the second step the "Chondrocytes apoptosis in Osteoarthritis"; in the third step the "Biomarkers of chondrocyte degeneration" and in the fourth step the "Autophagy". The overall research was focused on both *in vitro* and *in vivo* studies, and on the analysis of the obtained data.

3. Chondrocyte Apoptosis in Osteoarthritis {#sec3-ijms-16-20560}
==========================================

Apoptosis has been positively correlated with the severity of cartilage destruction and matrix depletion in human osteoarthritic tissue specimens \[[@B1-ijms-16-20560]\]. Freshly isolated chondrocytes from human OA cartilage exhibited morphological evidence of apoptosis, clear cytoplasmic, cell-surface blebs, altered nuclear shape, apoptotic bodies and a parallel loss of nuclear volume. Chondrocytes from normal donors did not show any cytoplasmic features of apoptotic cell death. These findings suggest that the OA chondrocytes demonstrate differences in predisposition towards apoptosis \[[@B4-ijms-16-20560],[@B7-ijms-16-20560]\]. In general studies of cartilage apoptosis several molecules are considered to be potential biomarkers but in the current literature only a few of them are discussed in this context. The studies published thus far have used a wide range of techniques, such as histology, terminal deoxynucleotidyl trasferase dUTP nick end labelling (TUNEL), analysis of caspase-3 expression, enzyme linked immunosorbent assays (ELISA), anti-poly (ADPribose) polymerase (anti-PARP), p85 and fluorescence activated cell sorter analysis (FACS) to examine the relationship between apoptosis and chondrocytes death in OA. In several studies, electron microscopy was used to identify ultrastructural changes attributable to apoptosis in chondrocytes within osteoarthritic cartilage \[[@B6-ijms-16-20560]\]. Apoptosis is induced through two main, alternative pathways: death receptor-mediated (or extrinsic) and mitochondria-dependent (or intrinsic), both lead to the activation of executor caspases \[[@B4-ijms-16-20560],[@B5-ijms-16-20560],[@B6-ijms-16-20560],[@B7-ijms-16-20560]\]. Caspases are a group of intracellular cysteine protease enzymes that destroy essential cellular proteins, leading to controlled cell death. There are two types of caspase enzymes: initiator caspases (caspases 2, 8, 9, and 10), activated through the apoptosis-signaling pathways, that activate the effector caspases (caspases 3, 6, and 7), which, in an expanding cascade, carry out apoptosis \[[@B10-ijms-16-20560],[@B11-ijms-16-20560],[@B12-ijms-16-20560]\]. Caspase 3 promotes the typical apoptosis features, including DNA fragmentation and cell death in many tissues including cartilage \[[@B9-ijms-16-20560],[@B10-ijms-16-20560],[@B11-ijms-16-20560],[@B12-ijms-16-20560]\]. The intrinsic pathway of apoptosis is regulated by mitochondrial parameters \[[@B13-ijms-16-20560],[@B14-ijms-16-20560],[@B15-ijms-16-20560]\]. Mitochondrial mediated apoptosis may initiate through the release of pro-apoptotic proteins into the cytosol due to mitochondrial dysfunction \[[@B13-ijms-16-20560],[@B14-ijms-16-20560],[@B15-ijms-16-20560]\]. However, mitochondria also contain anti-apoptotic proteins \[[@B14-ijms-16-20560]\]. Mitochondrial pro- and anti-apoptotic proteins belong to the B-cell lymphoma-2 (Bcl-2) family, and the balance between them controls apoptosis \[[@B14-ijms-16-20560],[@B16-ijms-16-20560]\]. The anti-apoptotic proteins Bcl-2 and Bcl-XL inhibit cytochrome c (cyt-c) release, whereas Bcl-2-associated X protein (Bax), Bcl-2 homologous antagonist/killer (Bak), and BH3 interacting domain death agonist (Bid), all pro-apoptotic proteins, promote its release from mitochondria. Cyt-c and deoxyadenosine triphosphate (dATP) bind to apoptotic protease activating factor (Apaf-1) to form a multimeric complex that recruits and activates procaspase 9, that in turn activates caspase 3, resulting in cell apoptosis ([Figure 1](#ijms-16-20560-f001){ref-type="fig"}) \[[@B3-ijms-16-20560],[@B17-ijms-16-20560]\]. The extrinsic pathway of apoptosis is activated by pro-apoptotic receptors on the cell surface \[[@B18-ijms-16-20560]\].

![The intrinsic pathway of apoptosis. Bcl-2: B-cell lymphoma-2; Bcl-XL: B-cell lymphoma-XL; Bax: Bcl-2-associated X protein; Bak: Bcl-2 homologous antagonist/killer; Bid: BH3 interacting domain death agonist; dATP: deoxyadenosine triphosphate; Apaf-1: apoptotic protease activating factor.](ijms-16-20560-g001){#ijms-16-20560-f001}

4. Biomarkers of Chondrocyte Degeneration {#sec4-ijms-16-20560}
=========================================

The molecular signals involved in the cartilage degeneration that is typical of OA are numerous and act via specific pathways that are shared with other molecules. Current OA biomarker research has focused on investigating the molecular markers involved in the degeneration of cartilage in OA, in order to develop new diagnostic and prognostic assays and facilitate the development of novel disease modifying therapies. In this brief review we report on molecular biomarkers of chondrocyte apoptosis in order to expand the knowledge that is currently available in this topic and provide a fresh perspective for apoptosis and biomarker researchers. Several studies have demonstrated that nitric oxide (NO) plays a role in chondrocyte apoptosis \[[@B19-ijms-16-20560],[@B20-ijms-16-20560]\]. NO is thought to operate through a mitochondria-dependent mechanism, enhancing the expression of pro-inflammatory cytokines involved in the breakdown of cartilage ECM \[[@B21-ijms-16-20560],[@B22-ijms-16-20560],[@B23-ijms-16-20560],[@B24-ijms-16-20560]\]. Chemical NO donors such as sodium nitroprusside (SNP) induce cell death in cultured human chondrocytes \[[@B24-ijms-16-20560]\]. Incubation of human articular chondrocytes with SNP has been shown to increase caspase-3 and caspase-7 gene expression and downregulate Bcl-2 mRNA levels, which is characteristic of apoptosis \[[@B21-ijms-16-20560],[@B22-ijms-16-20560],[@B23-ijms-16-20560],[@B24-ijms-16-20560]\]. SNP can induce apoptosis of human chondrocytes through cytoskeletal remodeling, mitogen-activated protein kinase kinase kinase-1/c-Jun N-terminal kinase (MEKK1/JNK) activation, Bax translocation, mitochondrial dysfunction and sequential caspase activation (caspase-9, -3 and -6), leading to DNA fragmentation \[[@B20-ijms-16-20560],[@B21-ijms-16-20560]\]. NO may be blocked by reactive oxygen species (ROS), and the balance between intracellular NO and ROS seems to determine if chondrocytes die through apoptosis or necrosis; indeed when the concentration of ROS is low, apoptosis occurs in the presence of NO. In contrast, high concentrations of ROS promote necrosis \[[@B25-ijms-16-20560]\]. Incubation with NO alone does not induce apoptotic cell death in chondrocytes \[[@B25-ijms-16-20560],[@B26-ijms-16-20560]\]. However, many reports indicate that NO, as a catabolic factor in OA, can induce cell death \[[@B25-ijms-16-20560],[@B26-ijms-16-20560]\]. Another study showed that apoptotic bodies isolated from NO-treated chondrocytes contain alkaline phosphatase, nucleoside triphosphate (NTP) pyrophosphohydrolase activities and can precipitate calcium \[[@B27-ijms-16-20560],[@B28-ijms-16-20560]\], and it is well known that calcium signalling is involved in almost cellular functions including metabolism, proliferation, differentiation, and also apoptosis \[[@B20-ijms-16-20560],[@B29-ijms-16-20560]\]. NO was shown to cause cell death and induce the tumour suppressor protein p53 via p38 mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB) \[[@B21-ijms-16-20560],[@B30-ijms-16-20560]\]. In addition to p53, c-myc may also regulate chondrocyte death in OA. In lesions of arthritic cartilage, *in situ* nick-end labeling (ISNEL), which identifies apoptotic cells, is associated with the expression of p53 and c-myc \[[@B31-ijms-16-20560]\], and in a canine model of OA, high levels of c-myc were shown in cartilage erosions \[[@B32-ijms-16-20560]\]. Another important biomarker of chondrocyte apoptosis is the death receptor Fas that induces cell death following ligation with Fas ligand (FasL) \[[@B33-ijms-16-20560]\]. Fas-mediated chondrocyte loss may contribute to cartilage degradation in OA and rheumatoid arthritis (RA) \[[@B20-ijms-16-20560],[@B27-ijms-16-20560],[@B28-ijms-16-20560]\]. Fas ligation by FasL is followed by recruitment of Fas-associated death domain (FADD) and subsequently of caspase 8 activation, which can be inhibited by the anti-apoptotic molecule FLICE inhibitory protein (Flip). Caspase 8 induces apoptosis by directly activating caspase 3 or by cleaving Bid, resulting in mitochondrial dysfunction and subsequent release of cyt-c and activation of caspases 9 and 3 ([Figure 2](#ijms-16-20560-f002){ref-type="fig"}) \[[@B3-ijms-16-20560],[@B6-ijms-16-20560]\]. Poly (ADP-ribose) polymerase 1 (PARP-1) is a nuclear DNA repair enzyme that is implicated in DNA repair and maintenance of genomic integrity. In apoptosis, PARP-1 is cleaved and inactivated by caspase-3, resulting in the formation of an N-terminal fragment containing most of the DNA binding domain and a C-terminal fragment containing the catalytic domain \[[@B10-ijms-16-20560],[@B11-ijms-16-20560],[@B12-ijms-16-20560]\]. Thus, the presence of C-terminal (89 kDa) PARP-1 fragment is considered an important biomarker of apoptosis \[[@B10-ijms-16-20560],[@B11-ijms-16-20560],[@B12-ijms-16-20560],[@B34-ijms-16-20560]\]. Authors investigated the histological aspects of the growth plate after injury and the relative caspase-3 expression by immunohistochemistry and histomorphometry; moreover western blot analysis was carried out to quantify the expression of caspase-3 and cleaved PARP-1. They concluded that caspase-3 and cleaved PARP-1 expression significantly increases in growth plate chondrocytes with a time-course progression \[[@B9-ijms-16-20560],[@B10-ijms-16-20560],[@B35-ijms-16-20560]\]. A recent study showed that Toll-like receptors 1/2 (TLR1/2) were expressed in degenerated chondrocytes in OA, and may react to cartilage matrix/chondrocyte-derived danger signals or degradation products. This leads to synthesis of pro-inflammatory cytokines, which stimulate further TLRs and cytokine expression, establishing a vicious circle. They also demonstrated that tumour necrosis factor-α (TNF-α) treatment increased TLR1 and TLR2 mRNA expression \[[@B36-ijms-16-20560],[@B37-ijms-16-20560],[@B38-ijms-16-20560]\]. If TNF-α mediates chondrocyte death is under observation. Data in literature showed that TNF-α stimulation of chondrocytes led to a small increase in the number of TUNEL- or ISNEL-positive cells \[[@B21-ijms-16-20560],[@B39-ijms-16-20560]\]. Moreover, DNA fragmentation in response to TNF-α was detected with a sensitive ELISA based technique when the chondrocytes were simultaneously stimulated with proteasome inhibitors \[[@B40-ijms-16-20560]\]. Therefore, TNF-α alone may have no effect on apoptosis \[[@B21-ijms-16-20560]\]. However, TNF-α in combination with actinomycin-D or Ro 31--8220 induces an increase in caspase-1 and -8 mRNA and protein levels \[[@B41-ijms-16-20560],[@B42-ijms-16-20560]\]. Instead, the transforming growth factor beta (TGF-β) in articular cartilage can work via two pathways, the ALK5/Smad2/3P and the ALK1/Smad1/5/8P route, the first being protective and the latter favouring chondrocyte terminal differentiation \[[@B43-ijms-16-20560]\]. Normally TGF-β has chondroprotective capabilities, but under specific conditions it should determine OA like changes in healthy articular cartilage \[[@B44-ijms-16-20560],[@B45-ijms-16-20560]\], shifting the molecular pathway from ALK5/Smad2/3P to ALK1/Smad1/5/8P, favouring terminal differentiation of chondrocytes and apoptosis \[[@B43-ijms-16-20560],[@B46-ijms-16-20560]\]. Various inflammatory conditions, including arthritis, are characterized by cartilage degradation through ECM destruction that should be also mediated by the small calcium-binding S100 proteins \[[@B21-ijms-16-20560],[@B47-ijms-16-20560]\]. The interaction of small calcium-bindingA4 (S100A4) with receptor for advanced glycation end products (RAGE) increases matrix metalloproteinase (MMP)-13 production in cartilage \[[@B47-ijms-16-20560]\], and upregulates MMP-13 and other MMPs in RA derived synovial fibroblasts \[[@B48-ijms-16-20560]\]. S100A4 was reported to bind tumour suppressor protein p53 and to regulate its function \[[@B49-ijms-16-20560]\], possibly promoting apoptosis. In OA cartilage histological analysis has revealed structural alterations and histochemical results have confirmed the presence of matrix calcification and reduction in proteoglycans, which reflects the presence of pathological changes. Moreover, these data coincided with an immunohistochemical increase in apoptotic cells, when compared to normal cartilage \[[@B4-ijms-16-20560],[@B7-ijms-16-20560]\]. The inflammation process causes stress to chondrocytes and induces cell death as a biological defense mechanism; on the other hand, survival of new chondrocytes increases in order to maintain cell homeostasis \[[@B4-ijms-16-20560],[@B7-ijms-16-20560],[@B50-ijms-16-20560],[@B51-ijms-16-20560]\]. Our hypothesis is that chondrocyte apoptosis could be secondary to cartilage degradation. It is supported by the fact that cell-matrix interaction is vital for chondrocyte survivability. Chondrocyte survival is thought to be mediated by integrins connecting the ECM components, like collagen, laminin and fibronectin, to various intracellular cytoskeletal proteins \[[@B6-ijms-16-20560]\]. Loss of this adhesion may trigger chondrocyte apoptosis. It is likely that disruption in chondrocyte-matrix interaction is either due to direct injury to the cartilage, causing biochemical changes or loss of ECM (e.g., denaturation of type II collagen, changes in fibronectin and other matrix protein expressions) \[[@B6-ijms-16-20560]\]. Moreover, the extent of chondrocyte apoptosis is positively correlated with expression of fibronectin, one of the key ECM molecules involved in communication between the cartilage cells and surrounding matrix, and up-regulation of expression of which is associated with the severity of articular cartilage damage \[[@B8-ijms-16-20560]\]. Decreased expression or availability of important ECM macromolecules in cartilage is sufficient to induce chondrocyte apoptosis and cause exacerbation of matrix damage \[[@B6-ijms-16-20560],[@B8-ijms-16-20560]\]. It has been observed that TNF-α-stimulation can cause dose-dependent depletion of proteoglycans \[[@B36-ijms-16-20560]\]. A chondroprotective agent is the mucinous glycoprotein product of the proteoglycan 4 (PRG4) gene, called lubricin \[[@B52-ijms-16-20560],[@B53-ijms-16-20560]\]. Lubricin is responsible for the boundary lubrication of articular cartilage \[[@B52-ijms-16-20560],[@B53-ijms-16-20560]\] and other joint parts \[[@B54-ijms-16-20560],[@B55-ijms-16-20560],[@B56-ijms-16-20560],[@B57-ijms-16-20560]\]. Thanks to its boundary-lubricating properties, lubricin prevents synoviocyte overgrowth, protects cartilage surfaces and prevents cartilage wear \[[@B58-ijms-16-20560]\]. Drug therapy with glucocorticoids (GCs) decreases the expression of lubricin and increases the expression of caspase-3 in rats, determining increased friction in the joint. Following physical activity the values return to normal levels compared to controls \[[@B50-ijms-16-20560],[@B59-ijms-16-20560]\]. Mechanical stimulation is able to stimulate release of lubricin in articular cartilage and to inhibit caspase-3 activity, preventing chondrocyte death \[[@B50-ijms-16-20560],[@B60-ijms-16-20560]\]. Nevertheless mechanical injury has been demonstrated to induce cell death and cartilage matrix degradation in bovine and human cartilage, through the release of ROS and proteoglycans, and the production of inflammatory and catabolic factors, such as MMPs, NO, "a disintegrin and metalloprotease with thrombospondin type I repeats-5" (ADAMTS-5) and interleukin-1β (IL-1β), \[[@B21-ijms-16-20560],[@B61-ijms-16-20560],[@B62-ijms-16-20560],[@B63-ijms-16-20560],[@B64-ijms-16-20560]\]. Moreover, western blot analysis revealed that static load-induced chondrocyte apoptosis was accompanied by increased phosphorylation of JNK, extracellular signal-regulated kinase 1/2 (ERK1/2), and p38 mitogen-activated protein kinase (MAPK). So the mitochondrial pathway is involved in mechanical stress-induced chondrocyte apoptosis \[[@B65-ijms-16-20560]\]. Glucocorticoids activate the caspase cascade and trigger Bax-mediated mitochondrial apoptosis in growth plate chondrocytes, causing growth retardation in young mice, indeed dexamethasone was found to increase the pro-apoptotic proteins Bcl-xS, Bad, and Bak as well as the proteolysis of Bid \[[@B50-ijms-16-20560],[@B60-ijms-16-20560],[@B66-ijms-16-20560]\]. Syndecan-4 is a transmembrane heparan sulfate proteoglycan and its immunostaining is abundant in both human and murine OA cartilage \[[@B46-ijms-16-20560],[@B67-ijms-16-20560]\]. *In vitro* studies have identified direct interactions between syndecan-4 and ADAMTS-5, and it is claimed that ADAMTS-5 activity, causing aggrecan breakdown in OA \[[@B68-ijms-16-20560]\], is dependent on MMP-3, mediating collagen type II breakdown and cartilage erosion, and the latter activity is controlled by syndecan-4 \[[@B67-ijms-16-20560],[@B69-ijms-16-20560],[@B70-ijms-16-20560]\].

![The extrinsic pathway of apoptosis. FasL: death-inducing molecule Fas ligand; FADD: Fas-associated death domain; Flip: FLICE inhibitory protein; Bid: BH3 interacting domain death agonist.](ijms-16-20560-g002){#ijms-16-20560-f002}

5. Autophagy {#sec5-ijms-16-20560}
============

Autophagy is a self-degradative process that is important for balancing sources of energy at critical times during development and in response to cell stress. Although autophagy is not a type of cell death, it is important for cartilage homeostasis. Generally autophagy promotes cell survival by adapting cells to stress conditions, but this process has also been considered as a non-apoptotic cell death program \[[@B71-ijms-16-20560],[@B72-ijms-16-20560],[@B73-ijms-16-20560]\]. Although autophagy shares some characteristics with apoptosis, such as absence of inflammation during the death process as well as ATP consumption, apoptosis is an essential physiological process that plays a critical role in development and tissue homeostasis, whereas autophagy means literally, to eat oneself, and in most circumstances, autophagy promotes cell survival by adapting cells to stress conditions, but at the same time, this process has also been considered as a non-apoptotic cell death program \[[@B72-ijms-16-20560]\]. During autophagy, parts of the cytoplasm and intracellular organelles are sequestered within characteristic autophagic vacuoles and are subsequently degraded by lysosomes. Recent data support the idea that autophagy can occur in combination with apoptosis in OA \[[@B21-ijms-16-20560],[@B72-ijms-16-20560]\], indeed Almonte-Becerril and collaborators demonstrated that in early stages of OA, chondrocytes from the superficial zone showed an increased expression of both apoptotic cell death and autophagic markers, even if authors suggested that autophagy is activated as an adaptive response to sublethal conditions, with the aim to avoid cell death. Afterward, as the degenerative process progresses, the conjunctly expression of both death markers in chondrocytes from both the superficial and middle zones, can be related with a defect in the reparation response of chondrocytes, due the increased activation of death signals, as well as the catabolic mechanisms prevalence. On the other hand, in the deep zone, authors evidenced the absence of autophagy and the increased apoptosis, that can be associated with the substitution of chondrocytes linked to the abnormal calcification of the cartilage present in late stage of OA. Therefore, authors concluded that the functional relationship between apoptosis and autophagy during OA pathogenesis is complex in the sense that, in early stages of OA, autophagy probably could be activated as an adaptive response that avoids cell death, whereas in late stages of OA, this process also could be conjunctly activated with apoptosis as an alternative pathway to cellular demise \[[@B72-ijms-16-20560]\]. Further studies are requires to precise and confirm the role of autophagic cell death, in the different stages of cartilage breakdown during the experimental OA model \[[@B21-ijms-16-20560],[@B72-ijms-16-20560]\]. In induced murine OA, it was shown that decreased expression of the autophagy markers correlate with proteoglycan loss and an increase in the levels of the apoptosis marker PARP p85 \[[@B46-ijms-16-20560],[@B74-ijms-16-20560]\]. In addition, in OA, autophagy is associated with an increased chondrocyte apoptosis and a reduction and loss of Unc-51-like kinase 1 (ULK1), an inducer of autophagy, Beclin1, a regulator of autophagy, and microtubule associated protein 1 light chain 3 (LC3), which executes autophagy ([Figure 3](#ijms-16-20560-f003){ref-type="fig"}, [Table 1](#ijms-16-20560-t001){ref-type="table"}) \[[@B20-ijms-16-20560],[@B74-ijms-16-20560]\]. Autophagy can be inhibited by interleukins cleaved by Nod-like receptor protein 3 (NLRP3)-dependent caspase-1 \[[@B20-ijms-16-20560],[@B75-ijms-16-20560],[@B76-ijms-16-20560]\]. Moreover several autophagy-inducing agents are object of recent researches as protective for OA. Among them, Tougu Xiaotong capsule inhibits tidemark replication and cartilage degradation by regulating chondrocyte autophagy and it could be a potential therapeutic agent for the reduction of cartilage degradation that occurs in osteoarthritis \[[@B77-ijms-16-20560]\]. Manipulation of Hypoxia-inducible factor 1-alpha (HIF-1α) and 2-alpha (HIF-2α) has been suggested as a promising approach to the treatment of OA. Indeed the increased HIF-1α and HIF-2α mediate the response of chondrocytes to hypoxia. HIF-1α regulates both autophagy and apoptosis, promoting the chondrocyte phenotype, maintaining chondrocyte viability, and supporting metabolic adaptation to a hypoxic environment. In contrast HIF-2α induces the expression of catabolic factors in chondrocytes, and enhances Fas expression leading to chondrocyte apoptosis and regulates autophagy in maturing chondrocytes \[[@B78-ijms-16-20560]\]. Recent studies showed that rapamycin activates autophagy in human chondrocytes preventing the development of OA *in vitro*, while the systemic and/or intra-articular injection of rapamycin reduces the severity of experimental osteoarthritis *in vivo* \[[@B79-ijms-16-20560]\], representing a potential therapeutic approach to prevent OA. Also glucosamine modulates and enhances autophagy pathway *in vitro* and *in vivo*, warranting other studies on the efficacy of glucosamine in OA \[[@B80-ijms-16-20560]\].

![Key features of autophagy. Cytoplasmic and intracellular organelles are sequestered within autophagic vacuoles to be degraded by lysosomes.](ijms-16-20560-g003){#ijms-16-20560-f003}

ijms-16-20560-t001_Table 1

###### 

Key features of different types of cell death.

  -------------------------------------------------------------------------------------------------------------------------------
  Apoptosis                                    Necrosis                                   Autophagy
  -------------------------------------------- ------------------------------------------ ---------------------------------------
  Rounding of cells;\                          Plasma membrane rupture;\                  Accumulation of autophagic vacuoles;\
  Plasma membrane blebbing;\                   Mitochondrial and cytoplasmic swelling;\   Lack of chromatin condensation;\
  Nuclear fragmentation;\                      No vesicle formation;\                     Late-stage mitochondrial swelling
  Chromatin condensation;\                     Moderate chromatin condensation            
  Reduction in cellular and nuclear volume;\                                              
  Apoptosis body formation;\                                                              
  Mitochondrial swelling (rare)                                                           

  -------------------------------------------------------------------------------------------------------------------------------

6. Conclusions {#sec6-ijms-16-20560}
==============

The diversity of the molecular signals that can induce cell death in chondrocytes in OA lead us to hypothesize that future therapeutic approaches should be aimed at neutralizing untimely and excessive apoptosis in articular cartilage. Developing novel biological and pharmaceutical agents that can counteract apoptosis and neutralise apoptosis-inducing molecules could potentially delay the progression of cartilage degeneration in OA. Identification of target molecules for gene therapy or biological or chemical reagent delivery to target sites could help prevent cartilage degeneration. Further longer-term *in vitro*, *in vivo* and clinical studies are needed to understand the precise role of apoptosis in cartilage degeneration mechanisms in OA and other osteoarticular disorders.
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